Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Optimal PEEP for Postoperative Oxygenation and Lung Aeration (ULTRASVENT-2) (ULTRASVENT-2)

Effect of Positive End-Expiratory Pressure (PEEP) Level on Postoperative Oxygenation and Lung Aeration Assessed by Lung Ultrasound Monitoring: A Multicenter Randomized Controlled Trial (ULTRASVENT-2)

The purpose of this multicenter, randomized controlled trial (ULTRASVENT-2) is to evaluate the effect of different positive end-expiratory pressure (PEEP) levels on postoperative oxygenation and lung aeration in adult patients undergoing elective non-cardiac and non-thoracic surgery under general anesthesia. Moving away from traditional binary outcomes, this study utilizes a continuous functional metric, the non-invasive oxygenation index SpO2/FiO2 (S/F ratio), as the primary endpoint to precisely capture the degree of respiratory function preservation.

Patients will be stratified into four distinct surgical cohorts based on the type and aggressiveness of the procedure: non-abdominal surgery, major open abdominal surgery, major laparoscopic abdominal surgery, and low-trauma laparoscopic surgery. This adaptive design aims to investigate how protective PEEP strategies interact with varying degrees of surgical trauma and intraoperative pneumoperitoneum, allowing the optimization of mechanical ventilation parameters for routine clinical practice.

Przegląd badań

Szczegółowy opis

Postoperative pulmonary complications remain a significant cause of morbidity and prolonged hospital stay after major surgical interventions under general anesthesia. While positive end-expiratory pressure (PEEP) is widely used to prevent alveolar collapse, the optimal target levels across different surgical sub-types remain controversial in modern anesthesiology. This trial aims to establish robust clinical evidence regarding perioperative lung protection using a comprehensive functional-anatomical approach.

Primary Endpoint and Measurement Standardization:

The primary outcome of the trial is the non-invasive oxygenation index, the S/F ratio (SpO2/Fraction of inspired oxygen), assessed exactly 2 hours post-extubation in the Post-Anesthesia Care Unit (PACU) and tracked dynamically over the first 24 hours of the postoperative period. To eliminate confounding variables and ensure absolute reproducibility across participating centers, the primary endpoint measurement is strictly standardized according to the following criteria:

  1. Room Air Breathing (FiO2 0.21): The evaluation is performed while the patient breathes atmospheric air without supplemental oxygen. This eliminates the masking of intrapulmonary shunts and prevents hyperoxia-induced absorption atelectasis.
  2. Patient Position: The patient must be placed in a strict supine position. This positioning represents the most physiologically challenging state for the respiratory system, inducing cranial displacement of the diaphragm and maximizing gravity-dependent alveolar collapse.
  3. Full Wakefulness Criteria: The measurement is executed only when the patient reaches a full awake status, defined as a modified Post Anesthesia Recovery Score (PARS) greater than 8, with the specific ventilation sub-score being equal to 2 (ability to deep breathe and cough freely). This cognitive and motor filter guarantees that any recorded functional impairment is caused by true parenchymal collapse rather than residual neuromuscular blockade or opioid-induced respiratory depression.

Differentiated Lung Ultrasound (LUS) Track:

To identify the anatomical substrate behind changes in gas exchange, regional lung aeration patterns will be recorded as the key secondary endpoint using a delta LUS score (postoperative score minus preoperative baseline). The diagnostic burden on the investigators is optimized using two parallel diagnostic tracks:

  • Express Track (Strata 1 and 4): A rapid, 2-zone simplified protocol focusing exclusively on the most gravity-dependent bilateral dorsal-basal sectors (Zone 6). This assessment takes 2 to 3 minutes and minimizes interference with routine PACU workflows.
  • Panoramic Mapping Track (Strata 2 and 3): A comprehensive 12-zone thoracic mapping performed under Intensive Care Unit (ICU) conditions. Furthermore, a nested validation sub-study will incorporate high-resolution chest computed tomography (CT) scans performed strictly based on clinical indications (such as refractory hypoxemia or suspected pneumonia). CT data will serve as the gold standard reference to calculate the true sensitivity and specificity of the 12-zone ultrasound findings.

Surgical Stratification and Sample Size Design:

Patients will be randomized in a 1:1 ratio to receive either a fixed standard (lower) PEEP or a fixed higher PEEP strategy throughout the intraoperative period (from intubation to extubation). Randomization is performed independently within 4 parallel strata to achieve a total sample size of 320 to 360 patients:

  • Strata 1: Non-abdominal surgery (n = 100; PEEP 5 cm H2O versus PEEP 8 cm H2O).
  • Strata 2: Major open abdominal surgery (n = 60 to 80; PEEP 5 cm H2O versus PEEP 8 cm H2O).
  • Strata 3: Major laparoscopic abdominal surgery (n = 60 to 80; PEEP 7 cm H2O versus PEEP 12 cm H2O).
  • Strata 4: Low-trauma laparoscopic surgery (n = 100; PEEP 5 cm H2O versus PEEP 12 cm H2O).

Statistical Analysis Framework:

Data processing will be conducted in the jamovi software environment using General Linear Models (GLM). The analysis will incorporate continuous and categorical baseline covariates (Body Mass Index, age, ASA physical status, and duration of surgery) to reduce residual variance. A key element of the statistical plan is the evaluation of interaction effects between the PEEP level and the specific surgical stratum to determine whether a higher PEEP provides a universal benefit or if its protective role is strictly dependent on the surgical phenotype.

Implementation Protocol Phases:

To guarantee data integrity and eliminate investigator bias, the project is structured into four consecutive logical phases:

Phase 1: Regulatory start, including central registration on ClinicalTrials.gov, Local Ethics Committee (LEC) submission and approval, and prospective publication of the formal Study Protocol manuscript.

Phase 2: Standardized hands-on calibration and training of the core investigator team (4 to 6 specialists) regarding precise zone identification and digital data entry.

Phase 3: A mandatory run-in period dedicated to inter-rater reliability testing. Each investigator must scan a test cohort, and the enrollment of randomized trial patients can begin only after achieving an inter-operator consensus threshold defined as a Cohen's Kappa coefficient greater than or equal to 0.7 and an absolute category agreement greater than or equal to 80%.

Phase 4: Active enrollment utilizing an adaptive recruitment strategy. The trial will commence by enrolling patients in high-volume, low-risk groups (Strata 1 and 4) to seamlessly refine logistical and database processes before activating the complex and labor-intensive ICU-based cohorts (Strata 2 and 3).

Typ studiów

Interwencyjne

Zapisy (Szacowany)

360

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

  • Nazwa: Ivan Shcheparev, MD, PhD
  • Numer telefonu: +7 901 908 90 88
  • E-mail: is22@list.ru

Lokalizacje studiów

    • Moscow
      • Moscow, Moscow, Rosja, 108814
        • Moscow Multi-disciplinary Clinical Center "Kommunarka"
        • Kontakt:
          • Ivan Shcheparev, MD, PhD
          • Numer telefonu: +7 901 908 90 88
          • E-mail: is22@list.ru

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Dorosły
  • Starszy dorosły

Akceptuje zdrowych ochotników

Nie

Opis

Inclusion Criteria:

  • Age greater than or equal to 18 years.
  • Planned elective non-cardiac and non-thoracic surgical intervention requiring general anesthesia with mechanical ventilation.
  • Airway protection utilizing an endotracheal tube.
  • Assignment to one of the four specific surgical strata: non-abdominal, major open abdominal, major laparoscopic abdominal, or low-trauma laparoscopic surgery.
  • Baseline lung ultrasound showing no pathological findings, corresponding to a total preoperative LUS score of 0.
  • Technical feasibility of performing a postoperative lung ultrasound within the first 2 hours after the completion of surgery.
  • Signed written informed consent to participate in the clinical trial.

Exclusion Criteria:

  • Planned cardiac or thoracic surgery (e.g., coronary artery bypass grafting, valve replacement, heart transplantation, lung resection, esophageal surgery).
  • Pneumothorax diagnosed before or during the surgical procedure.
  • Inability to adequately visualize the target dorsal-basal lung zones by ultrasound due to physical limitations (e.g., morbid obesity, massive surgical dressings, anatomical anomalies, or dermatological lesions in the scanning area).
  • Presence of hydrothorax detected on the baseline preoperative ultrasound.
  • Confirmed perioperative aspiration of gastric contents or other foreign material.
  • Any pathological changes identified during the baseline ultrasound of the dorsal-basal lung regions (a total preoperative LUS score greater than 0).
  • Requirement for massive blood transfusion during the surgery, defined according to local institutional criteria.
  • Surgical interventions directly involving or violating the diaphragm.
  • Expected inability to conduct reliable postoperative clinical and ultrasound assessments (e.g., need for deep sedation preventing wakefulness and contact, or planned transfer to another facility).

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Zapobieganie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Poczwórny

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Aktywny komparator: Standard PEEP Strategy
Patients randomized to this arm will receive a fixed, standard (lower) level of Positive End-Expiratory Pressure (PEEP) throughout the intraoperative period (from intubation to extubation). The specific PEEP value is determined strictly by the surgical stratum: 5 cm H2O for Strata 1 (Non-abdominal surgery), 5 cm H2O for Strata 2 (Major open abdominal surgery), 5 cm H2O for Strata 3 (Major laparoscopic abdominal surgery), and 5 cm H2O for Strata 4 (Low-trauma laparoscopic surgery). All other mechanical ventilation parameters remain standardized (tidal volume 6-8 mL/kg of ideal body weight).
Application of fixed PEEP levels calculated according to surgical aggressiveness and the presence of pneumoperitoneum. Standard PEEP arm utilizes PEEP values of 5 cm H2O. Higher PEEP arm utilizes protective PEEP values of 8 or 12 cm H2O. The assigned PEEP strategy is initiated immediately following endotracheal intubation and maintained continuously until extubation.
Eksperymentalny: Higher PEEP Strategy
Patients randomized to this arm will receive a fixed, higher level of Positive End-Expiratory Pressure (PEEP) designed for protective lung ventilation throughout the intraoperative period. The specific PEEP value is tailored to the surgical stratum and abdominal risk: 8 cm H2O for Strata 1 (Non-abdominal surgery), 8 cm H2O for Strata 2 (Major open abdominal surgery), 12 cm H2O for Strata 3 (Major laparoscopic abdominal surgery), and 12 cm H2O for Strata 4 (Low-trauma laparoscopic surgery). All other mechanical ventilation parameters remain standardized (tidal volume 6-8 mL/kg of ideal body weight).
Application of fixed PEEP levels calculated according to surgical aggressiveness and the presence of pneumoperitoneum. Standard PEEP arm utilizes PEEP values of 5 cm H2O. Higher PEEP arm utilizes protective PEEP values of 8 or 12 cm H2O. The assigned PEEP strategy is initiated immediately following endotracheal intubation and maintained continuously until extubation.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Non-invasive oxygenation index (SpO2/FiO2 ratio)
Ramy czasowe: Assessed at 3 time points: preoperatively (baseline); exactly 2 hours post-extubation; and 24 hours post-operation.

The primary functional outcome is the SpO2/FiO2 (S/F) ratio, a continuous metric indicating the degree of lung oxygenation. The S/F ratio is calculated by dividing the peripheral capillary oxygen saturation (SpO2) by the fraction of inspired oxygen (FiO2). To ensure standardization, postoperative measurements are performed on room air in a supine position. Measurements are recorded strictly when the patient achieves full wakefulness, which is verified using the modified Post Anesthesia Recovery Score (PARS) as a readiness criteria. The PARS scale ranges from a minimum of 0 to a maximum of 10, where higher scores indicate a better clinical recovery.

Note: The reported outcome is solely the S/F ratio value; the PARS score is used exclusively as a clinical condition to initiate the S/F measurement and is not aggregated into the final outcome value.

Assessed at 3 time points: preoperatively (baseline); exactly 2 hours post-extubation; and 24 hours post-operation.

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Incidence of Postoperative Pulmonary Complications (PPCs)
Ramy czasowe: From the end of surgery up to 7 days post-operation.
The composite clinical outcome evaluates the total percentage of patients developing at least one severe respiratory adverse event in the postoperative period. PPCs are strictly defined as the presence of one or more of the following: confirmed hospital-acquired pneumonia, prolonged requirement for supplemental oxygen therapy lasting longer than 24 hours, or the onset of refractory hypoxemia necessitating unexpected transfer to the Intensive Care Unit for non-invasive or invasive mechanical ventilation.
From the end of surgery up to 7 days post-operation.
Postoperative lung ultrasound score and aeration patterns
Ramy czasowe: Exactly 2 hours post-extubation in the Post-Anesthesia Care Unit (PACU) or Intensive Care Unit (ICU).

Evaluation of the absolute postoperative Lung Ultrasound (LUS) score to assess anesthesia-induced alveolar collapse. A differentiated protocol is used based on surgical strata.

Strata 1 and 4 use a 2-zone express protocol targeting dorsal-basal sectors (total scale range: minimum 0 to maximum 6).

Strata 2 and 3 use a comprehensive 12-zone panoramic thoracic mapping protocol (total scale range: minimum 0 to maximum 36).

For both LUS scales, higher scores indicate a worse outcome (more severe loss of lung aeration and atelectasis). Specific qualitative acoustic patterns (e.g., multiple B-lines, subpleural consolidations, or static bronchograms) are also recorded to validate the numerical LUS score.

Exactly 2 hours post-extubation in the Post-Anesthesia Care Unit (PACU) or Intensive Care Unit (ICU).
Incidence of Intraoperative Hemodynamic Instability
Ramy czasowe: Intraoperatively (from the moment of endotracheal intubation until extubation).
Frequency of intraoperative hemodynamic instability episodes directly related to mechanical ventilation settings, specifically measured as the requirement for the initiation or dose increase of vasopressor support (ephedrine, phenylephrine, or norepinephrine) to maintain a mean arterial pressure (MAP) greater than 65 mm Hg.
Intraoperatively (from the moment of endotracheal intubation until extubation).

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Główny śledczy: Ivan Shcheparev, MD, PhD, Moscow Multi-disciplinary Clinical Center "Kommunarka"
  • Dyrektor Studium: Denis Protsenko, MD, PhD, Professor, Moscow Multi-disciplinary Clinical Center "Kommunarka"
  • Krzesło do nauki: Efim Shifman, MD, PhD, Professor, Moscow Multi-disciplinary Clinical Center "Kommunarka"

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Publikacje ogólne

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

1 lipca 2026

Zakończenie podstawowe (Szacowany)

1 grudnia 2026

Ukończenie studiów (Szacowany)

20 grudnia 2026

Daty rejestracji na studia

Pierwszy przesłany

19 maja 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

23 maja 2026

Pierwszy wysłany (Rzeczywisty)

29 maja 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

29 maja 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

23 maja 2026

Ostatnia weryfikacja

1 maja 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

De-identified individual participant data (IPD) that underlie the results reported in the primary publication (including baseline characteristics, intraoperative mechanical ventilation parameters, lung ultrasound scores, and clinical postoperative outcomes) will be made publicly available to ensure absolute transparency and academic reproducibility.

Ramy czasowe udostępniania IPD

Data will become available immediately following the official publication of the primary trial results, with no specified end date.

Kryteria dostępu do udostępniania IPD

The dataset will be openly accessible to any researcher, clinician, or analyst interested in replicating the study findings, conducting systematic reviews, or performing secondary meta-analyses. The data will be hosted publicly, and no formal research proposal review or data use agreements are required for access.

Typ informacji pomocniczych dotyczących udostępniania IPD

  • PROTOKÓŁ BADANIA
  • ICF
  • CSR

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj